Japan's regulatory agency gets 20% funding increase:
This article was originally published in Clinica
The Pharmaceutical Affairs Bureau of Japan's Ministry of Health has been granted a 20.2% increase in funding in the fiscal 1996 budget to ¥,606 million ($90 million), reports Japan Medical Review. Among its priority projects for the current year, the bureau cites the international harmonisation of Japan's regulations covering in vitro diagnostics and medical devices as well as improving the safety of blood preparations.
You may also be interested in...
Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.
India’s Hilleman Laboratories says it’s aiming to develop an affordable vaccine that will target pregnant women in low- and middle-income countries to prevent Group B Streptococcus, a potentially fatal infection passed to babies during childbirth.
Chi-Med’s surufatinib has come up trumps in a second trial in neuroendocrine tumors, after the monitoring committee recommended an early halt following achievement of its PFS target in the pancreatic setting.